Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
Tobias KeßlerFelix SahmAhmed SadikDamian StichelAnne HertensteinGuido ReifenbergerAngela ZacherMichael SabelGhazaleh TabatabaiJoachim P. SteinbachUlrich SureDietmar KrexAnca‐L. GrosuMelanie Bewerunge‐HudlerDavid JonesStefan M. PfisterMichael WellerChristiane A. OpitzMartin BendszusAndreas von DeimlingMichael PlattenWolfgang Wick
Abstract
MGMT promoter methylation status does not define a molecularly distinct glioblastoma subpopulation among untreated tumors. Progressive mMGMT glioblastomas and mMGMT tumors of patients with short survival tend to have more unfavorable molecular profiles.
Metrics
Citation History
Topics
Related Documents
Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
Kessler, TobiasSahm, FelixSadik, AhmedStichel, DamianHertenstein, AnneReifenberger, GuidoZacher, AngelaSabel, MichaelTabatabai, GhazalehSteinbach, JoachimSure, UlrichKrex, DietmarGrosu, Anca-LBewerunge-Hudler, MelanieJones, DavidPfister, Stefan MWeller, MichaelOpitz, ChristianeBendszus, Martinvon Deimling, AndreasPlatten, MichaelWick, Wolfgang
OS07.1 Molecular differences in IDH wild type glioblastoma according to MGMT promoter methylation status
Tobias KeßlerFelix SahmAhmed SadikAnne HertensteinMartin BendszusAndreas von DeimlingMichael PlattenWolfgang Wick
XGBoost Improves Classification of MGMT Promoter Methylation Status in IDH1 Wildtype Glioblastoma
Nguyen Quoc Khanh LeDuyen ThiFang-Ying ChiuEdward Kien Yee YappHui‐Yuan YehCheng‐Yu Chen
MGMT promoter methylation in prognosis of patients with newly diagnosed IDH1 wildtype Glioblastoma
Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
Fatih IncekaraSebastian R. van der VoortHendrikus J. DubbinkPeggy N. AtmodimedjoRishi Nandoe TewarieGeert J. LycklamaArnaud J.P.E. VincentJohan M. KrosStefan KleinMartin J. van den BentMarion Smits